Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Sara Khalid, Sara Calderon-Larrañaga, Samuel Hawley, M Sanni Ali, Andrew Judge, Nigel Arden, Tjeerd van Staa, Cyrus Cooper, Muhammad Kassim Javaid & Daniel Prieto-Alhambra. (2018) Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database. Clinical Epidemiology 10, pages 1417-1431.
Read now
Read now
Gabriel Chodick, Sarah Sharman Moser & Inbal Goldshtein. (2016) Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost. Expert Review of Pharmacoeconomics & Outcomes Research 16:3, pages 359-370.
Read now
Read now
Ankita Modi, Shiva Sajjan & Sampada Gandhi. (2014) Challenges in implementing and maintaining osteoporosis therapy. International Journal of Women's Health 6, pages 759-769.
Read now
Read now
Kevin Jameson, Qiaoyi Zhang, Changgeng Zhao, Dena Rosen Ramey, Andrew M. Tershakovec, Stephen W. Gutkin & Elizabeth Marrett. (2014) Total and low-density lipoprotein cholesterol in high-risk patients treated with atorvastatin monotherapy in the United Kingdom: analysis of a primary-care database. Current Medical Research and Opinion 30:4, pages 655-665.
Read now
Read now
Véronique Rabenda, Michaël Hiligsmann & Jean-Yves Reginster. (2009) Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opinion on Pharmacotherapy 10:14, pages 2303-2315.
Read now
Read now
R. Rizzoli, O. Bruyere, J. B. Cannata-Andia, J.-P. Devogelaer, G. Lyritis, J. D. Ringe, B. Vellas & J.-Y. Reginster. (2009) Management of osteoporosis in the elderly. Current Medical Research and Opinion 25:10, pages 2373-2387.
Read now
Read now
Oliver Bock & Dieter Felsenberg. (2008) Bisphosphonates in the management of postmenopausal osteoporosis – optimizing efficacy in clinical practice. Clinical Interventions in Aging 3:2, pages 279-297.
Read now
Read now
Joyce A. Cramer, Stuart L. Silverman & Deborah T. Gold. (2007) Methodological considerations in using claims databases to evaluate persistence with bisphosphonates for osteoporosis. Current Medical Research and Opinion 23:10, pages 2369-2377.
Read now
Read now
Thomas W. Weiss, Scott C. Henderson, Colleen A. McHorney & Joyce A. Cramer. (2007) Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Current Medical Research and Opinion 23:9, pages 2193-2203.
Read now
Read now
Articles from other publishers (44)
Tyler P. Graf, Sherry Yue Qiu, Dhruv Varshney, Mei‐Li Laracuente, Erin M. Euliano, Pujita Munnangi, Brett H. Pogostin, Tsvetelina Baryakova, Arnav Garyali & Kevin J. McHugh. (2023) A Scalable Platform for Fabricating Biodegradable Microparticles with Pulsatile Drug Release. Advanced Materials 35:22.
Crossref
Crossref
Seihee Kim, Yoon-Sok Chung & Yunhwan Lee. (2022) Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis. Osteoporosis and Sarcopenia 8:3, pages 98-105.
Crossref
Crossref
Faisal I. Almohaileb & Zafar Rasheed. (2022) Comparing the Efficacies of Bisphosphonates’ Therapies for Osteoporosis Persistence and Compliance: A Systematic Review. Current Molecular Medicine 22:3, pages 274-284.
Crossref
Crossref
Hyunil Lee, Sangcheol Lee, Dokyung Kim, Weonmin Cho, Sungtan Cho, Siyeong Yoon & Soonchul Lee. (2021) Effect of Dosing Interval on Compliance of Osteoporosis Patients on Bisphosphonate Therapy: Observational Study Using Nationwide Insurance Claims Data. Journal of Clinical Medicine 10:19, pages 4350.
Crossref
Crossref
Matthew D. Budge, Priscilla H. Chan, Heather A. Prentice, Elizabeth W. Paxton & Ronald A. Navarro. (2021) The association between bisphosphonate use and aseptic revision risk in primary elective shoulder arthroplasty. Seminars in Arthroplasty: JSES 31:2, pages 255-262.
Crossref
Crossref
MARCUS MUÑOZ, KATHLEEN ROBINSON & AMAL SHIBLI-RAHHAL. (2020) Bone Health and Osteoporosis Prevention and Treatment. Clinical Obstetrics & Gynecology 63:4, pages 770-787.
Crossref
Crossref
J. Morley, A. Moayyeri, L. Ali, A. Taylor, M. Feudjo-Tepie, L. Hamilton & J. Bayly. (2019) Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporosis International 31:3, pages 533-545.
Crossref
Crossref
Arvind Sami & Bo Abrahamsen. (2019) The Latest Evidence from Vitamin D Intervention Trials for Skeletal and Non-skeletal Outcomes. Calcified Tissue International.
Crossref
Crossref
Stuart L. Silverman, E. Siris, D. Belazi, C. Recknor, A. Papaioannou, J. P. Brown, D. T. Gold, E. M. Lewiecki, G. Quinn, A. Balasubramanian, S. Yue, B. Stolshek & D. L. Kendler. (2018) Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study. Archives of Osteoporosis 13:1.
Crossref
Crossref
C. T. Yeam, S. Chia, H. C. C. Tan, Y. H. Kwan, W. Fong & J. J. B. Seng. (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporosis International 29:12, pages 2623-2637.
Crossref
Crossref
Ott Laius, Heti Pisarev, Katre Maasalu, Sulev Kõks & Aare Märtson. (2017) Adherence to osteoporosis medicines in Estonia—a comprehensive 15-year retrospective prescriptions database study. Archives of Osteoporosis 12:1.
Crossref
Crossref
Rita L. HuiAnnette L. AdamsFang NiuBruce EttingerDavid K. YiMalini ChandraJoan C. Lo. (2017) Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System. Journal of Managed Care & Specialty Pharmacy 23:4, pages 503-512.
Crossref
Crossref
Manju Chandran, Mcvin Cheen, Hao Ying, Tang Ching Lau & Matthew Tan. (2016) Dropping the Ball and Falling Off the Care Wagon. Factors Correlating With Nonadherence to Secondary Fracture Prevention Programs. Journal of Clinical Densitometry 19:1, pages 117-124.
Crossref
Crossref
Robert A Adler, Ghada El-Hajj Fuleihan, Douglas C Bauer, Pauline M Camacho, Bart L Clarke, Gregory A Clines, Juliet E Compston, Matthew T Drake, Beatrice J Edwards, Murray J Favus, Susan L Greenspan, Ross McKinneyJrJr, Robert J Pignolo & Deborah E Sellmeyer. (2016) Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 31:1, pages 16-35.
Crossref
Crossref
L. Karlsson, J. Lundkvist, E. Psachoulia, M. Intorcia & O. Ström. (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporosis International 26:10, pages 2401-2411.
Crossref
Crossref
Kristy Iglay, Xiting Cao, Panagiotis Mavros, Kruti Joshi, Shengsheng Yu & Kaan Tunceli. (2015) Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy. Clinical Therapeutics 37:8, pages 1813-1821.e1.
Crossref
Crossref
M. Pazianas, B. Abrahamsen, Y. Wang & R. G. G. Russell. (2012) Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. Osteoporosis International 23:12, pages 2873-2884.
Crossref
Crossref
M. H. H. Cheen, M. C. Kong, R. F. Zhang, F. M. H. Tee & M. Chandran. (2011) Adherence to osteoporosis medications amongst Singaporean patients. Osteoporosis International 23:3, pages 1053-1060.
Crossref
Crossref
E. Landfeldt, O. Ström, S. Robbins & F. Borgström. (2011) Adherence to treatment of primary osteoporosis and its association to fractures—the Swedish Adherence Register Analysis (SARA). Osteoporosis International 23:2, pages 433-443.
Crossref
Crossref
David H. Barlow. (2012) A persistent problem. Menopause 19:1, pages 8-9.
Crossref
Crossref
Lin Li, Andrew Roddam, Matthew Gitlin, Andrew Taylor, Susan Shepherd, Arran Shearer & Susan Jick. (2012) Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause 19:1, pages 33-40.
Crossref
Crossref
P. Hadji, V. Claus, V. Ziller, M. Intorcia, K. Kostev & T. Steinle. (2011) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporosis International 23:1, pages 223-231.
Crossref
Crossref
Kurt Lippuner, Richard F. Pollock, Jayne Smith-Palmer, Thomas Meury & William J. Valentine. (2011) A Review of the Cost Effectiveness of Bisphosphonates in the Treatment of Post-Menopausal Osteoporosis in Switzerland. Applied Health Economics and Health Policy 9:6, pages 403-417.
Crossref
Crossref
Erik Landfeldt, Andrea Lang, Sean Robbins & Oskar Ström. (2011) Gastrointestinal Tolerability and Patterns of Switching in Patients Treated for Primary Osteoporosis: The Swedish Adherence Register Analysis (SARA). Calcified Tissue International 89:3, pages 234-245.
Crossref
Crossref
T-C Lin, C-Y Yang, Y-H Kao Yang & S-J Lin. (2011) Alendronate Adherence and Its Impact on Hip-Fracture Risk in Patients With Established Osteoporosis in Taiwan. Clinical Pharmacology & Therapeutics 90:1, pages 109-116.
Crossref
Crossref
D. Prieto-Alhambra, M. K. Javaid, A. Judge, J. Maskell, A. Kiran, C. Cooper & N. K. Arden. (2010) Bisphosphonate use and risk of post-operative fracture among patients undergoing a total knee replacement for knee osteoarthritis: a propensity score analysis. Osteoporosis International 22:5, pages 1555-1571.
Crossref
Crossref
S. Lee, P. Glendenning & C. A. Inderjeeth. (2010) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporosis International 22:3, pages 741-753.
Crossref
Crossref
I. Imaz, P. Zegarra, J. González-Enríquez, B. Rubio, R. Alcazar & J. M. Amate. (2009) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporosis International 21:11, pages 1943-1951.
Crossref
Crossref
D. L. Kendler, L. Bessette, C. D. Hill, D. T. Gold, R. Horne, S. F. Varon, J. Borenstein, H. Wang, H.-S. Man, R. B. Wagman, S. Siddhanti, D. Macarios & H. G. Bone. (2009) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporosis International 21:5, pages 837-846.
Crossref
Crossref
R. Rizzoli. (2010) Management of the oldest old with osteoporosis. European Geriatric Medicine 1:1, pages 15-21.
Crossref
Crossref
Soo Jae YimYoung Koo LeeCheong Kwan KimHyun Seok SongHee Kyung Kang. (2010) Results of Osteoporotic Treatment Drug after Periarticular Fracture of Hip. Journal of the Korean Fracture Society 23:2, pages 167.
Crossref
Crossref
F.-E. Cotté, P. Fardellone, F. Mercier, A.-F. Gaudin & C. Roux. (2009) Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporosis International 21:1, pages 145-155.
Crossref
Crossref
Elena Segal & Sophia Ish-Shalom. (2009) Two years adherence to anti-osteoporotic medications in postmenopausal Israeli women. Archives of Gerontology and Geriatrics 49:3, pages 360-363.
Crossref
Crossref
C. Turbi, M. Casillas, M.A. Leal Muro, S. García, J. Tornero & J.L. Calatayud Carretero. (2008) Factores predictivos del cumplimiento del tratamiento diario con raloxifeno y alendronato. Revista Española de Enfermedades Metabólicas Óseas 17:5, pages 87-93.
Crossref
Crossref
E. Michael Lewiecki, Ann M. Babbitt, Veronica K. Piziak, Zafer E. Ozturk & Henry G. Bone. (2008) Adherence to and Gastrointestinal Tolerability of Monthly Oral or Quarterly Intravenous Ibandronate Therapy in Women with Previous Intolerance to Oral Bisphosphonates: A 12-Month, Open-Label, Prospective Evaluation. Clinical Therapeutics 30:4, pages 605-621.
Crossref
Crossref
Stuart L. Silverman & Deborah T. Gold. (2008) Compliance and persistence with osteoporosis therapies. Current Rheumatology Reports 10:2, pages 118-122.
Crossref
Crossref
Antonella Zambon, Gianluca Baio, Giampiero Mazzaglia, Luca Merlino & Giovanni Corrao. (2008) Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi‐state models. Pharmacoepidemiology and Drug Safety 17:3, pages 260-269.
Crossref
Crossref
DEBORAH T. GOLD & SAMANTHA SOLIMEO. 2008. Osteoporosis. Osteoporosis
1547
1553
.
Jonathan Adachi, Niall Lynch, Hans Middelhoven, Manjit Hunjan & Warren Cowell. (2007) The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review. BMC Musculoskeletal Disorders 8:1.
Crossref
Crossref
Stuart L. Silverman, Deborah T. Gold & Joyce A. Cramer. (2007) Reduced Fracture Rates Observed Only in Patients With Proper Persistence and Compliance With Bisphosphonate Therapies. Southern Medical Journal 100:12, pages 1214-1218.
Crossref
Crossref
Thomas W. Weiss & Colleen A. McHorney. (2007) Osteoporosis medication profile preference: results from the PREFER-US study. Health Expectations 10:3, pages 211-223.
Crossref
Crossref
J. A. Cramer, D. T. Gold, S. L. Silverman & E. M. Lewiecki. (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporosis International 18:8, pages 1023-1031.
Crossref
Crossref
Angelo A. Licata. (2007) Update on Therapy for Osteoporosis. Orthopaedic Nursing 26:3, pages 162-166.
Crossref
Crossref
Alun Cooper. (2006) Tackling compliance issues in osteoporosis treatment. Independent Nurse 2006:11.
Crossref
Crossref